Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Patent metadata

Field	Value
Publication number	US-9284367-B2
Application number	US-201213538823-A
Country	US
Kind code	B2
Filing date	Jun 29, 2012
Priority date	Dec 23, 2010
Publication date	Mar 15, 2016
Grant date	Mar 15, 2016

Abstract

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

First claim

What is claimed is:

1. A therapeutic preparation comprising natalizumab, the preparation shaped as a solid tissue penetrating member shaped and configured to penetrate and be inserted into an intestinal wall after oral ingestion by an application of mechanical force upon a surface of the solid tissue penetrating member from an expandable member operably coupled to the solid tissue penetrating member, wherein upon insertion, the tissue penetrating member remains in intestinal tissue to release natalizumab into the blood stream from the intestinal wall by degradation of the tissue penetrating member; wherein the tissue penetrating member is fabricated from the preparation itself.

2. The preparation of claim 1 , wherein all of the preparation is in solid form.

3. The preparation of claim 1 , wherein the preparation is adapted to be orally delivered in a swallowable capsule.

4. The preparation of claim 3 , wherein the preparation is adapted to be operably coupled to delivery means having a first configuration and a second configuration, the preparation being contained within the capsule in the first configuration and advanced out of the capsule and into the intestinal wall in the second configuration.

5. The preparation of claim 4 , wherein the delivery means comprises a least one expandable balloon having an expanded and a non-expanded state and the first configuration is the non-expanded state and the second configuration is the expanded state.

6. The preparation of claim 1 , wherein the preparation comprises a biodegradable material which degrades within the intestinal wall to release natalizumab into the blood stream.

7. The preparation of claim 6 , the biodegradable material comprises PGLA, a sugar or maltose.

8. The preparation of claim 1 , wherein the preparation comprises at least one pharmaceutical excipient.

9. The preparation of claim 8 , wherein the at least one pharmaceutical excipient comprises at least one of a binder, a preservative or a disintegrant.

10. The preparation of claim 9 , wherein the binder comprises PEG.

11. The preparation of claim 1 , wherein the tissue penetrating member comprises a biodegradable material which degrades within the intestinal wall to release natalizumab into the blood stream.

12. The preparation of claim 11 , wherein the biodegradable material comprises maltose or PGLA.

13. The preparation of claim 1 , wherein a weight percent of natalizumab in the tissue penetrating member comprises between about 8 to 12%.

14. The preparation of claim 1 , wherein the tissue penetrating member includes a retaining feature for retaining the tissue penetrating member within the intestinal wall after insertion.

15. The preparation of claim 14 , wherein the retaining feature comprises at least one of a barb or an inverse taper shape of the tissue penetrating member.

16. The preparation of claim 1 , wherein the natalizumab is contained in the tissue penetrating member in a shaped section.

17. The preparation of claim 16 , wherein the shaped section has a cylinder or pellet shape.

18. The preparation of claim 1 , wherein the tissue penetrating member has sufficient stiffness to be advanced completely into the intestinal wall by the application of a force to the tissue penetrating member.

19. The preparation of claim 1 , wherein the Cmax achieved by delivering the preparation by insertion into the intestinal wall is substantially greater than a Cmax achieved when the preparation is delivered orally without insertion into the intestinal wall.

20. The preparation of claim 19 , wherein the Cmax achieved by delivering the preparation by insertion into the intestinal wall is at least about 100 times greater than the Cmax achieved when the preparation is delivered orally without insertion into the intestinal wall.

21. The preparation of claim 1 , wherein the preparation is configured to produce a release of natalizumab of up to about 40 days.

22. The preparation of claim 21 , wherein the preparation is configured to release natalizumab to produce a selectable t½.

23. The preparation of claim 22 , wherein the t½ is about 40 days.

24. The preparation of claim 1 , wherein a dose of natalizumab in the preparation is in a range from about 1 to 5 mg.

25. The preparation of claim 24 , wherein a dose of natalizumab in the preparation is about 3 mg.

26. A solid therapeutic preparation comprising natalizumab, the preparation adapted for insertion into an intestinal wall after oral ingestion by the application of mechanical force upon a surface of the solid preparation from an expandable member operably coupled to the preparation, wherein upon insertion, the preparation remains in intestinal tissue and releases natalizumab into the bloodstream from the intestinal wall y degradation of the preparation to achieve a t½ that is greater than a t½ for orally ingested natalizumab that is not inserted into the intestinal wall by the application of a mechanical force upon the surface of the solid preparation; wherein a tissue penetrating member is fabricated from the preparation itself.

27. The preparation of claim 26 , wherein the t½ of the natalizumab inserted into the intestinal wall is at least about 10 times greater than the t½ for the orally ingested natalizumab that is not inserted into the intestinal wall.

Assignees

• Imran Mir
• Rani Therapeutics Llc

Inventors

• Imran Mir

Classifications

• A61M25/10

  Balloon catheters ({A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02;} inflatable balloons for placing stents or stent-grafts A61F2/958 {; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00}) · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title

• A61M2210/1042

  Alimentary tract (A61M2210/0618 takes precedence) · CPC title

• A61M31/002

  Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50) · CPC title

• A61M29/02

  Dilators made of swellable material {(balloon catheters for angioplasty A61M25/104)} · CPC title